Topics

Companies Related to "Bioasis Appoints Consultant Chief Medical Officer Nominates Medical" [Most Relevant Company Matches] RSS

08:19 EST 22nd January 2020 | BioPortfolio

Here are the most relevant search results for "Bioasis Appoints Consultant Chief Medical Officer Nominates Medical" found in our extensive corporate database of over 50,000 company records.

Showing "Bioasis Appoints Consultant Chief Medical Officer Nominates Medical" Companies 1–25 of 8,400+

Extremely Relevant

Vantage Oncology

Founded in October 2002, Vantage Oncology acquires, joint ventures, develops and operates radiation oncology centers of excellence. The Company was created in response to the growing need among cancer patients, hospitals and physicians for accessible and advanced radiation treatment therapies. Recent developments at Vantage include the establishment of multi-specialty oncology care organizations ...


Greater Medical Center Group

The Greater Medical Center Group (GMCG) is a provider of U.S. Clerkships for International Medical Students and Graduates. As a network of professionals and educators, GMCG's mission is to standardize the clinical experience of medical students educated abroad while providing support services to international medical schools. Key executives are Dr. Stephen M. Cohen, Chief Executive Officer; ...

Vantage Oncology, LLC

Founded in October 2002, Manhattan Beach, California-based Vantage Oncology, LLC owns, operates and manages radiation oncology centers of excellence. The company’s founding principles were to address the growing need among cancer patients, hospitals and physicians for easily accessible and advanced radiation treatment therapies. Vantage Oncology curre...


biOasis Technologies, Inc.

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing the xB3 platform, biOasisâ€...

biOasis Technologies Inc.

biOasis Technologies Inc. is a biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier (BBB). The delivery of therapeutics across the BBB represents the single greatest challenge in treating neurological disorders. The company is developing and commercializing a proprietary brain delivery ...

TScan Therapeutics

David Southwell, Chief Executive Officer David Southwell is the Chief Executive Officer of TScan and also serves as a member of the Company’s Board of Directors. Previously, David served as President and Chief Executive Officer of Inotek Pharmaceuticals through Inotek’s merger with Rocket Pharmaceuticals, a gene therapy-based biotechnology company. Previously, Mr. Southwell served as Ex...

Relevant

Medivizor

Medivizor offers a patent-pending, personalized health information platform for individuals with serious or chronic illnesses. Users of Medivizor are benefiting from custom content, cutting-edge research, clear and authoritative descriptions of treatment options, individual-matched clinical trials, social engagement, and much more. Professor Steven ...

Vmersion-Health

Vmersion-Health, developer of Gluco-Share, is a California Limited Partnership founded in 2011. Vmersion-Health develops and publishes social media applications for health-related causes, with a commitment to improved health through better communication and social support mechanisms. Joseph “Joe” Madden is president and Chief Executive Officer; J...

Origo Acquisition Corporation

Origo Acquisition Corporation is a public investment vehicle formed for the purpose of effecting a merger, acquisition or similar business combination. Origo is led by Chief Executive Officer Edward J. Fred, Chief Financial Officer Jose M. Aldeanueva and Directors Stephen B. Pudles, Jeffrey J. Gutovich and Barry Rodgers. Origo’s securities are quoted ...

Interface Biologics

Toronto, Canada – August 26, 2005 - Interface Biologics Inc. announced today the appointment of Richard W. Sullivan to the position of President and Chief Executive Officer of the Company.Mr. Sullivan brings more than 30 years of senior management and executive experience in the life sciences industry, having held key positions in early stage corporations since 1990. Most recently, as Chief Exec...

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.

Sucampo Pharmaceuticals, Inc. is a global pharmaceutical company focused on innovative research, discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified ...

MedDay

MedDay is a privately held biotechnology company developing new drugs for nervous system disorders. The company was founded in 2011 by Frédéric Sedel, MD, PhD (Chief Executive Officer), a leading neurologist and neuroscientist; and Guillaume Brion, MD (Chief Operating Officer) who has 25 years of experience in drug development and clinical research i...

Harbinger Capital Partners

Harbinger Capital Partners is a multi-billion dollar private investment fund based in New York which employs a fundamental, intensive research-based approach to investing. Harbinger Capital Partners is led by Phil Falcone who has been the Chief Executive Officer and Chief Investment Officer of funds affiliated with or managed by Harbinger Capital Partners ...

IntraBiotics Pharmaceuticals Inc.

On June 20, 2005, IntraBiotics Pharmaceuticals, Inc. announced that the Company was terminating all regular employees and ceasing all operations. It was also announced that the Company was appointing Hickey & Hill, Inc. to assume responsibilities for the day-to-day administration of the Company and that Mr. Hickey was to be designated Chief Executive Officer. Mr. Hickey has since been appointed Ch...

Healthcare Innovation Council

The Healthcare Innovation Council is an independent group of healthcare experts that generates and publicly shares innovative ideas about how U.S. hospitals and healthcare providers can meet escalating quality and financial pressures. The Council’s members are: Robert Burns, PhD, MBA, Chair of the Health Care Management Department at Wharton School, U...

SafeStitch Medical®, Inc.

Miami, Florida-based SafeStitch Medical, Inc. is a publicly traded medical device company founded by Charles J. Filipi M.D. and Jeffrey G. Spragens, initially with licensed technology from Creighton University, in 2005, to develop a prototype for a minimally invasive obesity procedure. In 2006, Phillip Frost M.D., Chairman and CEO of OPKO Health, In...

Sucampo Pharmaceuticals, Inc. and Takeda

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuj...

REVOLUTION Medicines

The REVOLUTION Medicines team brings deep expertise and a track record of building exceptional life sciences companies. In addition to Dr. Goldsmith, founding president and chief executive officer and Dr. Burke, founder and scientific advisory board chairman, the team includes: David Pompliano, Ph.D., founding chief scientific officer, who is a leading ...

Cagent Vascular, LLC

Cagent Vascular is leading the way for next generation technology for vessel dilatation. It is the second cardiovascular company formed by co-founders Carol Burns, President and CEO, Peter Schneider, MD, Vascular Surgeon, Chief Medical Officer and Robert Giasolli, VP of Research and Development. Visit www.cagentvascular.com.

AmeriLithium Corp.

Matthew Worrall, Chief Executive Officer

Cagent Vascular

Cagent Vascular is leading the way for next generation technology for vessel dilatation. It is the second cardiovascular company formed by co-founders Carol Burns, President & CEO, Peter Schneider, MD, Vascular Surgeon, Chief Medical Officer and Robert Giasolli, VP of Research and Development. Visit www.cagentvascular.com for more information.

Sucampo Pharmaceuticals, Inc. and Numab AG

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company based in Bethesda, Maryland, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids wa...

Sucampo Pharmaceuticals, Inc. and Abbott

Sucampo Pharmaceuticals, Inc., an international biopharmaceutical company based in Bethesda, Maryland, focuses on the development and commercialization of medicines based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymic (15-PGDH) transformation of certain fatty acids, was first identified ...

Palo Alto Investors, LLC

By: /s/ Will EdwardsName: Will Edwards, Chairman and Chief Investment Officer

K2M, Inc.

K2M, Inc. is an innovative spinal device company committed to the research, development, and commercialization of simplified solutions for the treatment of complex spinal pathologies and procedures. The company is recognized as a worldwide leader in providing unique technologies for the treatment of deformity, degenerative, trauma, and tumor spinal patient...


More From BioPortfolio on "Bioasis Appoints Consultant Chief Medical Officer Nominates Medical"

Quick Search

Corporate Database Quicklinks